NRx Pharma Q3 net loss narrows to $6.1M; advances NRX-101 and ketamine plans

NRX Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.35

Q3 net loss $6.1M vs $9.1M YoY; R&D expense $3.3M, G&A $2.5M; cash $8.9M.
Near completion of Phase 2b/3 NRX-101 trial for treatment-resistant bipolar depression; top-line data expected shortly after last patient visit.
Plan to submit NDA for IV ketamine (NRX-100) in Q1 2024; manufacturing partnership with Nephron signed.
Received term sheet for up to $30M anchor financing for a ketamine-focused spinoff entity.
Identified naked shorting disparities of ~1-1.5M shares; counsel instructed to demand closure of uncovered positions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NRX Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the third fiscal quarter ending September 30, 2023 and provided a business update.

View on SEC.gov

Browse all earnings releases →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-117735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.